Viatris Share Price (NASDAQ: VTRS)

$10.62

▲

-0.07

(-0.65%)

Last updated on August 16, 2025 at 1:29 AM IST

$₹

Check the interactive Viatris Stock chart to analyse performance

Viatris stock performance

as on August 16, 2025 at 1:29 AM IST

Today's Low:$10.56
Today's High:$10.78
$10.62
0.56%
Downside
Day's Volatility :2.04%
Upside
1.48%
52 Weeks Low:$6.85
52 Weeks High:$13.55
$10.62
35.5%
Downside
52 Weeks Volatility :49.45%
Upside
21.62%

Viatris Stock Returns

Period	Viatris Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	21.12%	2.3%	0.0%
6 Months	-2.3%	-5.8%	0.0%
1 Year	-10.31%	-10.9%	0.0%
3 Years	0.38%	2.8%	-11.6%

Viatris Inc. Key Stats

Check Viatris key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$10.69
Open	$10.735
Today's High	$10.78
Today's Low	$10.56
Market Capitalization	$11.5B
Today's Volume	$9.2M
52 Week High	$13.55
52 Week Low	$6.85
Revenue TTM	$14.1B
EBITDA	$4.1B
Earnings Per Share (EPS)	$-2.93
Dividend Yield	4.95%
Profit Margin	-24.57%
Quarterly Earnings Growth YOY	-0.71%
Return On Equity TTM	-19.77%

Stock Returns calculator for Viatris Stock including INR - Dollar returns

The Viatris stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Viatris investment value today

Current value as on today

₹93,982

Returns

₹6,018

(-6.02%)

Returns from Viatris Stock

₹10,228 (-10.23%)

Dollar Returns*

₹4,210 (+4.21%)

Indian investors sentiment towards Viatris Stock

-9%

Period: Jul 18, 2025 to Aug 17, 2025. Change in 30 Days versus previous period

Search interest for Viatris Stock from India on INDmoney has decreased by -9% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Viatris Stock

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential Value Fund Direct Plan Growth	8686950	3963334.07	1.24%
Motilal Oswal S&P 500 Index Fund Direct Growth	9487	-4.36	0.02%
ICICI Prudential MNC Fund Direct Growth	329126	-29308.67	1.50%

Global Institutional Holdings in Viatris Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
12.41%
BlackRock Inc
8.32%
T. Rowe Price Associates, Inc.
6.39%
Davis Selected Advisers
5.57%
State Street Corp
5.27%
Geode Capital Management, LLC
2.67%

Analyst Recommendation on Viatris Stock

Rating

Trend

Hold

7%Buy

57%Hold

35%Sell

Based on 14 Wall street analysts offering stock ratings for Viatris(by analysts ranked 0 to 5 stars)

Viatris Share Price Target

What analysts predicted

Upside of 6.27%

Target:

$11.29

Current:

$10.62

Viatris share price target is $11.29, a slight Upside of 6.27% compared to current price of $10.62 as per analysts' prediction.

Viatris Stock Insights

Price Movement
In the last 1 month, VTRS stock has moved up by 19.5%
Increasing Revenue
Revenue is up for the last 2 quarters, 3.25B → 3.58B (in $), with an average increase of 9.2% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -3.04B → -4.6M (in $), with an average increase of 66030.4% per quarter
VTRS vs HLN (1 yr)
In the last 1 year, Viatris Inc. has experienced a drawdown of -9.0%, however Haleon Plc Spon Ads resisted the overall trend and outperformed by 8.6%
VTRS vs HLN (3 yr)
In the last 3 years, Haleon Plc Spon Ads has given 57.9% return, outperforming this stock by 57.7%
Price to Sales
ForVTRS every $1 of sales, investors are willing to pay $0.9, whereas for Haleon Plc Spon Ads, the investors are paying $4.0 for every $1 of sales.

Viatris Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$11.5B	↑ 0.58%
Net Income	$16.8M	↓ 95.23%
Net Profit Margin	0.15%	↓ 2.93%

	FY20	Y/Y Change
Revenue	$11.9B	↑ 3.87%
Net Income	$-669.9M	↓ 4087.5%
Net Profit Margin	-5.61%	↓ 5.76%

	FY21	Y/Y Change
Revenue	$17.9B	↑ 49.73%
Net Income	$-1.3B	↑ 89.45%
Net Profit Margin	-7.1%	↓ 1.49%

	FY22	Y/Y Change
Revenue	$16.3B	↓ 9.08%
Net Income	$2.1B	↓ 263.79%
Net Profit Margin	12.78%	↑ 19.88%

	FY23	Y/Y Change
Revenue	$15.4B	↓ 5.14%
Net Income	$54.7M	↓ 97.37%
Net Profit Margin	0.35%	↓ 12.43%

	FY24	Y/Y Change
Revenue	$14.7B	↓ 4.46%
Net Income	$-634.2M	↓ 1259.41%
Net Profit Margin	-4.3%	↓ 4.65%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$3.7B	↓ 4.21%
Net Income	$113.9M	↓ 114.88%
Net Profit Margin	3.11%	↑ 23.13%

	Q2 FY24	Q/Q Change
Revenue	$3.8B	↑ 3.64%
Net Income	$-326.4M	↓ 386.57%
Net Profit Margin	-8.6%	↓ 11.71%

	Q3 FY24	Q/Q Change
Revenue	$3.7B	↓ 1.54%
Net Income	$94.8M	↓ 129.04%
Net Profit Margin	2.54%	↑ 11.14%

	Q4 FY24	Q/Q Change
Revenue	$3.5B	↓ 5.62%
Net Income	$-516.5M	↓ 644.83%
Net Profit Margin	-14.64%	↓ 17.18%

	Q1 FY25	Q/Q Change
Revenue	$3.3B	↓ 7.76%
Net Income	$-3.0B	↑ 488.96%
Net Profit Margin	-93.48%	↓ 78.84%

	Q2 FY25	Q/Q Change
Revenue	$3.6B	↑ 10.07%
Net Income	$-4.6M	↓ 99.85%
Net Profit Margin	-0.13%	↑ 93.35%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$4.4B	↓ 2.8%

	FY20	Y/Y Change
Profit	$3.8B	↓ 14.57%

	FY21	Y/Y Change
Profit	$5.6B	↑ 46.85%

	FY22	Y/Y Change
Profit	$6.5B	↑ 16.53%

	FY23	Y/Y Change
Profit	$6.4B	↓ 0.9%

	FY24	Y/Y Change
Profit	$5.6B	↓ 12.66%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$1.5B	↓ 6.62%

	Q2 FY24	Q/Q Change
Profit	$1.5B	↓ 0.72%

	Q3 FY24	Q/Q Change
Profit	$1.5B	↓ 2.27%

	Q4 FY24	Q/Q Change
Profit	$1.2B	↓ 16.74%

	Q1 FY25	Q/Q Change
Profit	$1.2B	↓ 4.43%

	Q2 FY25	Q/Q Change
Profit	$1.3B	↑ 15.76%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$1.8B	↓ 22.97%
Investing Cash Flow	$-525.4M	↓ 56.59%
Financing Cash Flow	$-1.2B	↑ 7.16%

	FY20	Y/Y Change
Operating Cash Flow	$1.2B	↓ 31.71%
Investing Cash Flow	$-301.1M	↓ 42.69%
Financing Cash Flow	$-605.7M	↓ 48.19%

	FY21	Y/Y Change
Operating Cash Flow	$3.0B	↑ 144.92%
Investing Cash Flow	$-117.8M	↓ 60.88%
Financing Cash Flow	$-3.0B	↑ 397.28%

	FY22	Y/Y Change
Operating Cash Flow	$3.0B	↓ 2.13%
Investing Cash Flow	$1.5B	↓ 1390.75%
Financing Cash Flow	$-3.9B	↑ 28.75%

	FY23	Y/Y Change
Operating Cash Flow	$2.8B	↓ 5.18%
Investing Cash Flow	$-764.1M	↓ 150.25%
Financing Cash Flow	$-2.3B	↓ 40.64%

	FY24	Y/Y Change
Operating Cash Flow	$2.3B	↓ 17.74%
Investing Cash Flow	$1.8B	↓ 335.66%
Financing Cash Flow	$-4.3B	↑ 88.12%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$614.6M	↑ 28.2%
Investing Cash Flow	$-154.3M	-
Financing Cash Flow	$-425.6M	↓ 54.04%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$379.1M	↓ 38.32%
Investing Cash Flow	$375.8M	↓ 343.55%
Financing Cash Flow	$-847.9M	↑ 99.22%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$826.5M	↑ 118.02%
Investing Cash Flow	$1.7B	↑ 365.11%
Financing Cash Flow	$-1.6B	↑ 93.03%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$482.7M	↓ 41.6%
Investing Cash Flow	$-168.7M	↓ 109.65%
Financing Cash Flow	$-1.4B	↓ 13.23%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$535.5M	↑ 10.94%
Investing Cash Flow	$-65.1M	↓ 61.41%
Financing Cash Flow	$-467.0M	↓ 67.12%

Viatris Technicals Summary

Sell

Neutral

Buy

Viatris is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Viatris Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Viatris Inc.	19.21%	-2.3%	-10.31%	0.38%	-35.07%
Haleon Plc Spon Ads	1.26%	-3.4%	-1.23%	61.37%	30.23%
United Therapeutics Corporation	6.83%	-16.01%	-10.17%	39.52%	76.09%
Zoetis Inc.	4.57%	-1.51%	-16.46%	-9.09%	-2.82%
Neurocrine Biosciences Inc.	0.81%	16.61%	-10.35%	24.21%	17.48%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Viatris Inc.	224.4	NA	0.07	2.26	-0.2	0.02	0.05	13.36
Haleon Plc Spon Ads	21.56	21.44	3.08	0.49	0.09	0.05	0.01	1.77
United Therapeutics Corporation	12.22	12.22	1.43	26.95	0.19	0.13	NA	158.65
Zoetis Inc.	26.24	26.53	2.49	6.32	0.53	0.15	0.01	11.21
Neurocrine Biosciences Inc.	38.85	39.32	0.27	6.74	0.13	0.09	NA	27.22

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Viatris Inc.	Hold	$11.5B	-35.07%	224.4	-24.57%
Haleon Plc Spon Ads	Buy	$43.5B	30.23%	21.56	13.81%
United Therapeutics Corporation	Buy	$14.2B	76.09%	12.22	40.36%
Zoetis Inc.	Buy	$67.6B	-2.82%	26.24	27.83%
Neurocrine Biosciences Inc.	Buy	$13.0B	17.48%	38.85	13.88%

Viatris Dividend announcements

Viatris Dividends September, 2025
In the quarter ending September,2025. Viatris has declared dividend of $0.12

About Viatris Inc.

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Organization	Viatris
Employees	32000
CEO	Mr. Scott Andrew Smith Ph.D.
Industry	Health Technology

Key Management of Viatris Inc.

Name	Title
Mr. Scott Andrew Smith Ph.D.	CEO & Director
Ms. Theodora Mistras	Chief Financial Officer
Mr. Paul B. Campbell	Chief Accounting Officer, Senior VP & Corporate Controller
Mr. Brian S. Roman	Chief Legal Officer
Dr. Corinne M. Le Goff M.B.A., Pharm.D.	Chief Commercial Officer
Mr. Ramkumar V. Rayapureddy	Chief Information Officer
Mr. Andrew Enrietti	Chief People Officer
Mr. Menassie Taddese M.B.A.	President of Emerging Markets

Important FAQs about investing in VTRS Stock from India :

What is Viatris share price today?

Viatris share price today is $10.62 as on August 16, 2025 at 1:29 AM IST at the close of the market. Viatris share today touched a day high of $10.78 and a low of $10.56.

What is the 52 week high and 52 week low for Viatris share?

Viatris share touched a 52 week high of $13.55 and a 52 week low of $6.85. Viatris stock price today, August 16, 2025 at 1:29 AM IST is trending at $10.62, lower by 21.62% versus the 52 week high.

How to invest in Viatris Stock (VTRS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Viatris on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Viatris Shares that will get you 0.1412 shares as per Viatris share price of $10.62 per share as on August 16, 2025 at 1:29 AM IST.

What is the minimum amount required to buy Viatris Stock (VTRS) from India?

Indian investors can start investing in Viatris (VTRS) shares with as little as ₹87.492 or $1 (as of August 18, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.92 in Viatris stock (as per the Rupee-Dollar exchange rate as on August 18, 2025). Based on Viatris share’s latest price of $10.62 as on August 16, 2025 at 1:29 AM IST, you will get 0.9416 shares of Viatris. Learn more about fractional shares .

What are the returns that Viatris has given to Indian investors in the last 5 years?

Viatris stock has given -35.07% share price returns and 17.06% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?